Innoviva FY2026 EPS Estimate Lowered by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has lowered its FY2026 earnings per share estimate for Innoviva, now expecting $1.66, down from $1.84, while maintaining an "Overweight" rating and a $26.00 price target.
• Innoviva recently reported an earnings per share of $0.77 for the last quarter, exceeding the consensus estimate of $0.57, with revenue of $100.28 million compared to the forecast of $87.10 million.
• Institutional investors hold 99.12% of Innoviva's stock, with significant interests from firms such as Geode Capital Management and Hussman Strategic Advisors, indicating strong institutional support.

Innoviva, Inc. (NASDAQ:INVA - Free Report) - Cantor Fitzgerald reduced their FY2026 earnings per share estimates for Innoviva in a research note issued on Thursday, August 7th. Cantor Fitzgerald analyst S. Seedhouse now expects that the biotechnology company will post earnings of $1.66 per share for the year, down from their prior forecast of $1.84. Cantor Fitzgerald currently has a "Overweight" rating and a $26.00 price target on the stock. The consensus estimate for Innoviva's current full-year earnings is $0.33 per share.

A number of other equities research analysts also recently commented on the stock. HC Wainwright started coverage on shares of Innoviva in a research report on Monday, July 14th. They issued a "buy" rating and a $40.00 price objective for the company. Wall Street Zen upgraded shares of Innoviva from a "hold" rating to a "buy" rating in a research report on Wednesday, April 30th.

Innoviva Stock Performance

Shares of NASDAQ:INVA traded down $0.14 during trading on Friday, reaching $18.32. The company had a trading volume of 98,029 shares, compared to its average volume of 817,763. The firm has a market capitalization of $1.15 billion, a price-to-earnings ratio of 59.10 and a beta of 0.38. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.48 and a quick ratio of 2.30. Innoviva has a fifty-two week low of $16.67 and a fifty-two week high of $22.00. The stock's fifty day moving average price is $19.89 and its 200 day moving average price is $18.75.

Innoviva (NASDAQ:INVA - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported $0.77 EPS for the quarter, topping analysts' consensus estimates of $0.57 by $0.20. Innoviva had a net margin of 10.44% and a return on equity of 18.99%. The firm had revenue of $100.28 million during the quarter, compared to the consensus estimate of $87.10 million.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC raised its position in shares of Innoviva by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 1,522,622 shares of the biotechnology company's stock worth $30,593,000 after buying an additional 102,194 shares during the period. Vise Technologies Inc. purchased a new stake in Innoviva during the 2nd quarter worth approximately $238,000. Profund Advisors LLC grew its holdings in Innoviva by 13.6% during the 2nd quarter. Profund Advisors LLC now owns 12,269 shares of the biotechnology company's stock worth $246,000 after acquiring an additional 1,473 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Innoviva in the second quarter valued at about $1,585,000. Finally, Hussman Strategic Advisors Inc. lifted its position in shares of Innoviva by 25.0% in the 2nd quarter. Hussman Strategic Advisors Inc. now owns 210,000 shares of the biotechnology company's stock worth $4,219,000 after buying an additional 42,000 shares during the last quarter. 99.12% of the stock is currently owned by hedge funds and other institutional investors.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.